References
- Sjögren's Syndrome. Primer on the rheumatic diseases. 12th ed, J. H Klippel, C. M Weyand, L. J Crofford, J. H Stone. Arthritis Foundation, Atlanta 2001; 377–84
- Vitali C., Bombardieri S., Moutsopoulos H. M., Balestrieri G., Bencivelli W., Bernstein R. M., et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36: 340–7
- Omdal R., Wildhagen K., Hansen T., Gunnarsson R., Kristoffersen G. Anti‐CD20 therapy of treatment‐resistant Wegener's granulomatosis: favorable but temporary response. Scand J Rheumatol 2005; 34: 229–32
- Van Vollenhoven R. F., Gunnarsson I., Welin‐Henriksson E., Sundelin B., Osterborg A., Jacobson S. H., et al. Biopsy‐verified response of severe lupus nephritis to treatment with rituximab (anti‐CD20 monoclonal antibody) plus cyclophosphamide after biopsy‐documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004; 33: 423–7
- Kneitz C., Wilhelm M., Tony H. P. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol 2004; 33: 82–6
- Gottenberg J. E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., , for the Club Rhumatismes et Inflammation (CRI), et al. Tolerance and short‐term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913–20
- Silverman G. J., Weisman S. Rituximab therapy and autoimmune disorders. Arthritis Rheum 2003; 48: 1484–92
- Zaja F., De Vita S., Russo D., Michelutti A., Fanin R., Ferraccioli G., et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002; 46: 2252–4
- Pijpe J., Van Imhoff G., Spijkervet F., Roodenburg J., Wolbink G., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome. An open‐label phase II study. Arthritis Rheum 2005; 52: 2740–50
- Somer B. G., Tsai D. E., Downs L., Weinstein B., Schuster S. J. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003; 49: 394–8
- Ramos‐Casals M., López‐Guillermo A., Brito‐Zerón P., Cervera R., Font J. Treatment of B‐cell lymphoma with rituximab in two patients with Sjogren's syndrome associated with hepatitis C virus infection. Lupus 2004; 13: 969–71
- Pijpe J., Van Imhoff G., Vissink A., Van Der Wal J. E., Kluin P. M., Kallenberg C. G., et al. Changes in salivary gland immunohistology and function after rituximab mono‐therapy in a patient with Sjogren's syndrome and associated MALT‐lymphoma. Ann Rheum Dis 2005; 64: 958–60